Hemostemix Inc.
HMTXF
$0.06
-$0.01-8.76%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 142.52% | 61.17% | 57.94% | -3.50% | -8.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 188.79% | 72.30% | 61.26% | -19.69% | -42.98% |
| Operating Income | -188.79% | -72.30% | -61.26% | 19.69% | 42.98% |
| Income Before Tax | -64.65% | -59.96% | -93.70% | -2.51% | 26.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.65% | -59.96% | -93.70% | -2.51% | 37.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.65% | -59.96% | -93.70% | -2.51% | 37.39% |
| EBIT | -188.79% | -72.30% | -61.26% | 19.69% | 42.98% |
| EBITDA | -188.81% | -72.31% | -61.28% | 19.68% | 42.97% |
| EPS Basic | -32.30% | -35.44% | -73.57% | 15.63% | 42.91% |
| Normalized Basic EPS | -27.78% | -9.09% | -44.23% | 24.68% | 10.00% |
| EPS Diluted | -32.30% | -35.44% | -73.57% | 15.63% | 42.91% |
| Normalized Diluted EPS | -27.78% | -9.09% | -44.23% | 24.68% | 10.00% |
| Average Basic Shares Outstanding | 40.76% | 25.19% | 10.41% | 11.76% | 8.25% |
| Average Diluted Shares Outstanding | 40.76% | 25.19% | 10.41% | 11.76% | 8.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |